Evidence map›Paper›PMID 24053345›Full record

ReviewExpert review of neurotherapeutics2013

Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Jens O Watzlawik, Bharath Wootla, Meghan M Painter, Arthur E Warrington, Moses Rodriguez

Abstract readReview
In one paragraph

Review in Expert review of neurotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Dose-dependent inhibition of demyelination and microglia activation by IVIG.Annals of clinical and translational neurology · 2016
    Article
  7. Article
  8. Article
  9. Remyelination Therapy in Multiple Sclerosis.Frontiers in neurology · 2015
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jens O WatzlawikDepartments of Neurology and Immunology, Mayo Clinic, College of Medicine, 200 First Street, S.W., Rochester, MN 55905, USA.
Bharath Wootla
Meghan M Painter
Arthur E Warrington
Moses Rodriguez
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Nanopore Biosensor for Kinetics of Reparative Antibodies on Plasma MembranesR01GM092993 · NIGMS · UNIVERSITY OF MINNESOTA · PI OH, SANG-HYUN · 2010 to 2013
$1.6M
Genetic Analysis of Spontaneous RemyelinationR01NS048357 · NINDS · MAYO CLINIC ROCHESTER · PI BIEBER, ALLAN JAMES · 2008 to 2011
$1.0M
Clinical Translation of a Neuron Protective Recombinant Human AntibodyR21NS073684 · NINDS · MAYO CLINIC ROCHESTER · PI RODRIGUEZ, MOSES · 2011 to 2012
$434k
NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1TR000135NCI NIH HHS CA 1060ANIGMS NIH HHS R01 GM092993NINDS NIH HHS R01 NS048357NINDS NIH HHS R21 NS073684
6 · The paper itself

Abstract

Immunoglobulins with germline sequences occur in invertebrates and vertebrates and are named naturally occurring autoantibodies (NAbs). NAbs may target foreign antigens, self- or altered self-components and are part of the normal immunoglobulin repertoire. Accumulating evidence indicates that naturally occurring antibodies can act as systemic surveillance molecules, which tag, damaged or stressed cells, invading pathogens and toxic cellular debris for elimination by the immune system. In addition to acting as detecting molecules, certain types of NAbs actively signal in different cell types with a broad range of responses from induction of apoptosis in cancer cells to stimulation of remyelination in glial cells. This review emphasizes functions and characteristics of NAbs with focus on remyelination-promoting mouse and human antibodies. Human remyelination-promoting NAbs are potential therapeutics to combat a wide spectrum of disease processes including demyelinating diseases like multiple sclerosis. We will highlight the identified glycosphingolipid (SL) antigens of polyreactive remyelination-promoting antibodies and their proposed mechanism(s) of action. The nature of the identified antigens suggests a lipid raft-based mechanism for remyelination-promoting antibodies with SLs as most essential raft components. However, accumulating evidence also suggests involvement of other antigens in stimulation of remyelination, which will be discussed in the text.

Indexed as

AnimalsAutoantibodiesAutoantigensDemyelinating DiseasesHumansImmunoglobulin MMiceMyelin SheathAutoantibodiesAutoantigensImmunoglobulin M

Identifiers

PMID24053345
PMCPMC3909667
OpenAlexW2161167250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.